AU2017207757B2 - Cyclic dinucleotides for treating conditions associated with STING activity such as cancer - Google Patents
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer Download PDFInfo
- Publication number
- AU2017207757B2 AU2017207757B2 AU2017207757A AU2017207757A AU2017207757B2 AU 2017207757 B2 AU2017207757 B2 AU 2017207757B2 AU 2017207757 A AU2017207757 A AU 2017207757A AU 2017207757 A AU2017207757 A AU 2017207757A AU 2017207757 B2 AU2017207757 B2 AU 2017207757B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- independently selected
- purin
- certain embodiments
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277273P | 2016-01-11 | 2016-01-11 | |
| US62/277,273 | 2016-01-11 | ||
| US201662436759P | 2016-12-20 | 2016-12-20 | |
| US62/436,759 | 2016-12-20 | ||
| PCT/US2017/013066 WO2017123669A1 (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017207757A1 AU2017207757A1 (en) | 2018-08-23 |
| AU2017207757B2 true AU2017207757B2 (en) | 2021-05-27 |
Family
ID=58010371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017207757A Active AU2017207757B2 (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10604542B2 (OSRAM) |
| EP (1) | EP3402801B1 (OSRAM) |
| JP (1) | JP6867395B2 (OSRAM) |
| KR (2) | KR102789862B1 (OSRAM) |
| CN (1) | CN109451740B (OSRAM) |
| AU (1) | AU2017207757B2 (OSRAM) |
| BR (1) | BR112018013808A2 (OSRAM) |
| CA (1) | CA3011528A1 (OSRAM) |
| CL (1) | CL2018001870A1 (OSRAM) |
| CO (1) | CO2018008196A2 (OSRAM) |
| DK (1) | DK3402801T3 (OSRAM) |
| EA (1) | EA036421B1 (OSRAM) |
| ES (1) | ES3046957T3 (OSRAM) |
| FI (1) | FI3402801T3 (OSRAM) |
| HR (1) | HRP20251050T1 (OSRAM) |
| IL (1) | IL260427B (OSRAM) |
| LT (1) | LT3402801T (OSRAM) |
| MX (1) | MX2018008266A (OSRAM) |
| MY (1) | MY194058A (OSRAM) |
| PE (1) | PE20181330A1 (OSRAM) |
| PL (1) | PL3402801T3 (OSRAM) |
| PT (1) | PT3402801T (OSRAM) |
| RS (1) | RS67188B1 (OSRAM) |
| SG (1) | SG11201805888SA (OSRAM) |
| SI (1) | SI3402801T1 (OSRAM) |
| SM (1) | SMT202500412T1 (OSRAM) |
| WO (1) | WO2017123669A1 (OSRAM) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20171448A1 (es) | 2015-03-10 | 2017-10-02 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| MX2018001814A (es) | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
| HRP20251050T1 (hr) * | 2016-01-11 | 2025-11-07 | Innate Tumor Immunity, Inc. | Ciklični dinukleotidi za liječenje stanja povezanih s aktivnošću sting kao što je rak |
| CN114751950B (zh) | 2016-03-18 | 2025-04-18 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| MX392605B (es) | 2016-07-06 | 2025-03-11 | Invox Pharma Ltd | Compuestos, composiciones y metodos para el tratamiento de enfermedades. |
| FI3506884T4 (fi) | 2016-08-30 | 2024-12-23 | Dana Farber Cancer Inst Inc | Lääkkeenantokoostumuksia ja niiden käyttötapoja |
| GEP20217285B (en) | 2016-10-04 | 2021-08-10 | Merck Sharp & Dohme | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| CA3058134A1 (en) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| US11259980B2 (en) | 2017-07-31 | 2022-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Soft inflatable exosuit for knee rehabilitation |
| JP2020529421A (ja) | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ |
| US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
| KR102782200B1 (ko) | 2017-08-30 | 2025-03-17 | 에이제이 사이언시즈 (이씽) 코., 엘티디 | 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드 |
| KR102812783B1 (ko) * | 2017-08-31 | 2025-05-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| WO2019046511A1 (en) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11180524B2 (en) | 2017-09-14 | 2021-11-23 | Janssen Biopharma, Inc. | Modified nucleoside phosphoramidites |
| JP7212683B2 (ja) * | 2017-10-10 | 2023-01-25 | ブリストル－マイヤーズ スクイブ カンパニー | 抗がん剤としての環状ジヌクレオチド |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| KR20200098511A (ko) | 2017-11-10 | 2020-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Sting 조절제 화합물, 및 제조 및 사용 방법 |
| US11685761B2 (en) | 2017-12-20 | 2023-06-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| EP3505527A1 (en) * | 2017-12-29 | 2019-07-03 | Invivogen | Cyclic dinucleotides for cytokine induction |
| US10519187B2 (en) * | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| JP7250808B2 (ja) * | 2018-03-08 | 2023-04-03 | ブリストル－マイヤーズ スクイブ カンパニー | 抗がん剤としての環状ジヌクレオチド |
| US20210015915A1 (en) | 2018-03-23 | 2021-01-21 | Takeda Pharmaceutical Company Limited | Sting modulator compounds with sulfamate linkages, and methods of making and using |
| JP7326319B2 (ja) | 2018-04-03 | 2023-08-15 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物 |
| EP3774765A4 (en) | 2018-04-03 | 2021-12-29 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| ES2929415T3 (es) | 2018-05-25 | 2022-11-29 | Incyte Corp | Compuestos heterocíclicos tricíclicos como activadores de STING |
| US12291548B2 (en) | 2018-07-10 | 2025-05-06 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| US11691990B2 (en) | 2018-08-16 | 2023-07-04 | Eisai R&D Management Co., Ltd | Salts of compounds and crystals thereof |
| PT3848054T (pt) | 2018-09-06 | 2025-04-03 | Daiichi Sankyo Co Ltd | Conjugados anticorpo-fármaco de derivados de dinucleótidos cíclicos |
| CA3111784A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Methods and compositions for the treatment of disease with immune stimulatory conjugates |
| WO2020057546A1 (zh) | 2018-09-21 | 2020-03-26 | 上海迪诺医药科技有限公司 | 环状二核苷酸类似物、其药物组合物及应用 |
| US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020089815A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| WO2020117739A1 (en) * | 2018-12-04 | 2020-06-11 | Bristol-Myers Squibb Company | Process for the preparation of a cyclic dinucleotide |
| US12129267B2 (en) | 2019-01-07 | 2024-10-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| US12060384B2 (en) | 2019-02-05 | 2024-08-13 | Bristol-Myers Squibb Company | Synthesis of 1,2,5-tri-o-benzoyl-3-dibenzylamino-3-deoxyribose as intermediate for producing 3′-amino-3′-deoxyadenosine and 3′-amino-3′-deoxyguanosine and the protected derivatives thereof |
| WO2020229982A1 (en) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| EP3993834A1 (en) | 2019-07-05 | 2022-05-11 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| CN114206898B (zh) * | 2019-07-25 | 2024-06-25 | 百济神州有限公司 | 作为sting激动剂的环状二核苷酸 |
| WO2021067644A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| JP7787514B2 (ja) | 2019-12-26 | 2025-12-17 | 国立大学法人東海国立大学機構 | ポリヌクレオチド及び医薬組成物 |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| JPWO2021177438A1 (OSRAM) | 2020-03-06 | 2021-09-10 | ||
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| WO2021216698A1 (en) * | 2020-04-21 | 2021-10-28 | Duke University | Compositions and methods for the treatment of pain |
| CA3178252A1 (en) | 2020-05-11 | 2021-11-18 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
| TW202216211A (zh) | 2020-07-01 | 2022-05-01 | 美商希沃爾拜克治療公司 | 抗asgr1抗體共軛物及其用途 |
| EP4295917A3 (en) | 2020-08-07 | 2024-02-28 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| TW202227479A (zh) | 2020-09-02 | 2022-07-16 | 日商第一三共股份有限公司 | 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶 |
| EP4228657A4 (en) * | 2020-10-15 | 2024-11-20 | The Regents Of The University Of Michigan | Crystalline polymorphic forms of sting agonists associated with metal ions capable of modulating an immune response |
| KR102466750B1 (ko) | 2020-10-23 | 2022-11-15 | 아주대학교산학협력단 | 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| WO2022094262A1 (en) | 2020-10-30 | 2022-05-05 | Avacta Life Sciences Limited | Fap-activated serum extended half-life therapeutic conjugates |
| KR20230106606A (ko) | 2020-11-09 | 2023-07-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 항체 약물 접합체 |
| AU2022302611A1 (en) | 2021-06-30 | 2024-02-15 | Kyowa Kirin Co., Ltd. | Polynucleotide and medicinal composition |
| EP4488378A1 (en) | 2022-03-02 | 2025-01-08 | Daiichi Sankyo Company, Limited | Method for producing fc-containing molecule |
| CN119744182A (zh) | 2022-08-29 | 2025-04-01 | 第一三共株式会社 | 包含突变Fc区的抗体药物偶联物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014179335A1 (en) * | 2013-04-29 | 2014-11-06 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| NZ537686A (en) | 2002-06-20 | 2007-01-26 | Nippon Suisan Kaisha Ltd | A beta2 agonist prodrug having reduced side effects |
| WO2005089777A1 (en) * | 2004-03-15 | 2005-09-29 | Karaolis David K R | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| CA2873402C (en) * | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| SG11201407875UA (en) | 2012-06-08 | 2014-12-30 | Aduro Biotech | Compostions and methods for cancer immunotherapy |
| AU2013358892B2 (en) * | 2012-12-13 | 2018-06-21 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| DK2996473T3 (da) | 2013-05-18 | 2019-11-04 | Aduro Biotech Inc | Sammensætninger og fremgangsmåder til aktivering af "stimulator af interferon-gen"-afhængig signalering |
| US9642830B2 (en) | 2013-10-21 | 2017-05-09 | Drexel University | Use of sting agonists to treat hepatitis B virus infection |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| WO2015077534A1 (en) | 2013-11-22 | 2015-05-28 | Massachusetts Institute Of Technology | Photovoltaic power balancing and differential power processing |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| CA2950033A1 (en) | 2014-06-04 | 2015-12-10 | Glaxosmithkline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| PL3233882T3 (pl) | 2014-12-16 | 2020-04-30 | Kayla Therapeutics | Fluorowane cykliczne dinukleotydy do indukcji cytokin |
| US20170340658A1 (en) | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| PE20171448A1 (es) | 2015-03-10 | 2017-10-02 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon |
| MX2018001814A (es) | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
| NZ738202A (en) | 2015-12-03 | 2019-07-26 | Glaxosmithkline Ip Dev Ltd | Cyclic purine dinucleotides as modulators of sting |
| HRP20251050T1 (hr) * | 2016-01-11 | 2025-11-07 | Innate Tumor Immunity, Inc. | Ciklični dinukleotidi za liječenje stanja povezanih s aktivnošću sting kao što je rak |
| CN114751950B (zh) | 2016-03-18 | 2025-04-18 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
-
2017
- 2017-01-11 HR HRP20251050TT patent/HRP20251050T1/hr unknown
- 2017-01-11 ES ES17704338T patent/ES3046957T3/es active Active
- 2017-01-11 PE PE2018001267A patent/PE20181330A1/es unknown
- 2017-01-11 PL PL17704338.7T patent/PL3402801T3/pl unknown
- 2017-01-11 JP JP2018536116A patent/JP6867395B2/ja active Active
- 2017-01-11 EP EP17704338.7A patent/EP3402801B1/en active Active
- 2017-01-11 LT LTEPPCT/US2017/013066T patent/LT3402801T/lt unknown
- 2017-01-11 AU AU2017207757A patent/AU2017207757B2/en active Active
- 2017-01-11 KR KR1020187022863A patent/KR102789862B1/ko active Active
- 2017-01-11 SI SI201731621T patent/SI3402801T1/sl unknown
- 2017-01-11 MX MX2018008266A patent/MX2018008266A/es unknown
- 2017-01-11 CN CN201780015198.2A patent/CN109451740B/zh active Active
- 2017-01-11 RS RS20250892A patent/RS67188B1/sr unknown
- 2017-01-11 SG SG11201805888SA patent/SG11201805888SA/en unknown
- 2017-01-11 MY MYPI2018702369A patent/MY194058A/en unknown
- 2017-01-11 DK DK17704338.7T patent/DK3402801T3/da active
- 2017-01-11 SM SM20250412T patent/SMT202500412T1/it unknown
- 2017-01-11 FI FIEP17704338.7T patent/FI3402801T3/fi active
- 2017-01-11 BR BR112018013808-8A patent/BR112018013808A2/pt active Search and Examination
- 2017-01-11 PT PT177043387T patent/PT3402801T/pt unknown
- 2017-01-11 EA EA201891565A patent/EA036421B1/ru not_active IP Right Cessation
- 2017-01-11 KR KR1020257010190A patent/KR20250049441A/ko active Pending
- 2017-01-11 US US15/748,685 patent/US10604542B2/en active Active
- 2017-01-11 WO PCT/US2017/013066 patent/WO2017123669A1/en not_active Ceased
- 2017-01-11 CA CA3011528A patent/CA3011528A1/en active Pending
-
2018
- 2018-07-04 IL IL260427A patent/IL260427B/en active IP Right Grant
- 2018-07-10 CL CL2018001870A patent/CL2018001870A1/es unknown
- 2018-08-02 CO CONC2018/0008196A patent/CO2018008196A2/es unknown
-
2020
- 2020-01-31 US US16/778,281 patent/US10961270B2/en active Active
-
2021
- 2021-01-28 US US17/160,578 patent/US11505571B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014179335A1 (en) * | 2013-04-29 | 2014-11-06 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017207757B2 (en) | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer | |
| EP3621624B1 (en) | Cyclic di-nucleotide compounds as sting agonists | |
| US20190345191A1 (en) | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity | |
| JP6596146B2 (ja) | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド化合物 | |
| US11685761B2 (en) | Cyclic di-nucleotide compounds as sting agonists | |
| ES2894228T3 (es) | Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4' | |
| AU2019288495B2 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| TWI808092B (zh) | 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 | |
| JP2023022165A (ja) | インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド | |
| CA3082351A1 (en) | Sting modulator compounds, and methods of making and using | |
| WO2021178818A2 (en) | Therapeutic agents and conjugates thereof | |
| KR102902754B1 (ko) | 엑토뉴클레오티다제 저해제 및 이의 사용 방법 | |
| WO2025199428A1 (en) | Mannose receptor ligand-tropomyosin receptor b ligand conjugates for drug delivery | |
| NZ790347A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| HK40022356A (en) | Cyclic di-nucleotides as stimulator of interferon genes modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |